The Cytotoxic Effects of Preserved and Preservative-Fr Corneal and Conjunctival EpitheliumIn Vitroand Chloride Homologs in Ocular Surface TissuesIn Vivo

Current Eye Research

37, 145-154

DOI: 10.3109/02713683.2011.626909

Citation Report

#	Article	IF	Citations
1	A Phase II Study on the Duration and Stability of the Intraocular Pressure-Lowering Effect and Tolerability of Tafluprost Compared With Latanoprost. Journal of Ocular Pharmacology and Therapeutics, 2010, 26, 97-104.	1.4	47
2	Tafluprost: The First Preservative-Free Prostaglandin to Treat Open-Angle Glaucoma and Ocular Hypertension. Annals of Pharmacotherapy, 2012, 46, 1506-1510.	1.9	27
3	Corneal Epithelial Cell Viability Following Exposure to Ophthalmic Solutions Containing Preservatives and/or Antihypertensive Agents. Advances in Therapy, 2012, 29, 874-888.	2.9	20
4	Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma. Clinical Ophthalmology, 2012, 7, 7.	1.8	8
5	Loteprednol Etabonate Ophthalmic Gel 0.5% Following Cataract Surgery: Integrated Analysis of Two Clinical Studies. Advances in Therapy, 2013, 30, 907-923.	2.9	9
6	Glaucoma therapy and ocular surface disease. Current Opinion in Ophthalmology, 2013, 24, 136-143.	2.9	85
7	Ocular Toxicity of Benzalkonium Chloride Homologs Compared with Their Mixtures. Journal of Toxicologic Pathology, 2013, 26, 343-349.	0.7	8
8	Effect of Preservative-Free Tafluprost on Keratocytes, Sub-Basal Nerves, and Endothelium: A Single-Blind One-Year Confocal Study on NaÃ¯ve or Treated Glaucoma and Hypertensive Patients Versus a Control Group. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 821-825.	1.4	20
9	Ocular pharmacokinetics of bimatoprost formulated in DuraSite compared to bimatoprost 0.03% ophthalmic solution in pigmented rabbit eyes. Clinical Ophthalmology, 2013, 7, 1549.	1.8	15
10	Latanoprost in the treatment of glaucoma. Clinical Ophthalmology, 2014, 8, 1967.	1.8	70
11	Comparison of Corneal Safety and Intraocular Pressureâ€“Lowering Effect of Tafluprost Ophthalmic Solution with Other Prostaglandin Ophthalmic Solutions. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 340-345.	1.4	8
12	Increased Corneal Epithelial Permeability After Overnight Sleep. , 2014, 55, 5718.		7
13	Design and Characterization of an Ocular Topical Liposomal Preparation to Replenish the Lipids of the Tear Film. Investigative Ophthalmology and Visual Science, 2014, 55, 7839-7847.	3.3	42
14	In VitroEffects of Preserved and Unpreserved Anti-Allergic Drugs on Human Corneal Epithelial Cells. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 790-798.	1.4	27
15	Cationorm shows good tolerability on human HCE-2 corneal epithelial cell cultures. Experimental Eye Research, 2014, 120, 82-89.	2.6	20
16	Ocular Surface Cytotoxicity and Safety Evaluation of Tafluprost, a Recently Developed Anti-Glaucoma Prostaglandin Analog. Ophthalmology and Eye Diseases, 2014, 6, OED.S12445.	1.2	10
17	Stromal opacity secondary to preservative in dilating drops â€“ A case report and review of literature. Journal of Acute Disease, 2014, 3, 77-79.	0.3	1
18	Mechanisms of benzalkonium chloride toxicity in a human trabecular meshwork cell line and the protective role of preservativeâ€free tafluprost. Clinical and Experimental Ophthalmology, 2015, 43, 164-172.	2.6	22

#	Article	IF	Citations
19	Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose–response phenomenon. Clinical Ophthalmology, 2016, 10, 373.	1.8	5
20	Preparation and optimisation of anionic liposomes for delivery of small peptides and cDNA to human corneal epithelial cells. Journal of Microencapsulation, 2016, 33, 391-399.	2.8	22
21	Acute cytotoxic effects of marketed ophthalmic formulations on human corneal epithelial cells. International Journal of Pharmaceutics, 2016, 511, 73-78.	5.2	14
22	In vitro and in vivo corneal effects of latanoprost combined with brimonidine, timolol, dorzolamide, or brinzolamide. European Journal of Pharmacology, 2016, 787, 43-46.	3.5	5
23	Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa. European Journal of Pharmacology, 2016, 788, 12-20.	3.5	20
24	Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015Â% and Timolol 0.5Â% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies. Clinical Pharmacokinetics, 2016, 55, 485-494.	3.5	16
25	Ocular Surface Disease in Patients under Topical Treatment for Glaucoma. European Journal of Ophthalmology, 2017, 27, 694-704.	1.3	45
26	Management of Glaucoma in Patients with Ocular Surface Disease. , 2018, , 125-138.		0
27	High Permeability and Intercellular Space Widening With Brimonidine Tartrate Eye Drops in Cultured Stratified Human Corneal Epithelial Sheets. Cornea, 2018, 37, 242-247.	1.7	3
28	Effects of sustained daily latanoprost application on anterior chamber anatomy and physiology in mice. Scientific Reports, 2018, 8, 13088.	3.3	0
29	Preservatives in glaucomaÂmedication. British Journal of Ophthalmology, 2018, 102, 1497-1503.	3.9	83
30	Safety data on in situ gelling bimatoprost loaded nanovesicular formulations. Data in Brief, 2019, 25, 104361.	1.0	1
31	An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy. Scientific Reports, 2019, 9, 4282.	3.3	9
32	Experimental Evaluation of Travoprost-Induced Changes in Biomechanical Behavior of Ex-Vivo Rabbit Corneas. Current Eye Research, 2019, 44, 19-24.	1.5	9
33	Profiling ocular surface responses to preserved and nonâ€preserved topical glaucoma medications: A 2â€year randomized evaluation study. Clinical and Experimental Ophthalmology, 2020, 48, 973-982.	2.6	27
34	Corneal damage and its recovery after instillation of preservative-free versus preserved latanoprost eye drops. Cutaneous and Ocular Toxicology, 2020, 39, 158-164.	1.3	7
35	Biomechanical Effects of Two Forms of PGF2Î± on Ex-vivo Rabbit Cornea. Current Eye Research, 2021, 46, 452-460.	1.5	5
36	The treatment of glaucoma using topical preservative-free agents: an evaluation of safety and tolerability. Expert Opinion on Drug Safety, 2021, 20, 453-466.	2.4	16

#	Article	IF	Citations
37	Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol. HRB Open Research, 2019, 2, 15.	0.6	22
38	Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study. PLoS ONE, 2015, 10, e0129419.	2.5	5
40	Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study. Open Ophthalmology Journal, 2016, 10, 146-153.	0.2	11
41	Myopia Outcome Study of Atropine in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, randomised clinical trial protocol. HRB Open Research, 0, 2, 15.	0.6	1
42	Antimicrobial Effectiveness in Eye Drops: Limited Sterility versus Reduction in Microbial Count. PDA Journal of Pharmaceutical Science and Technology, 2020, 74, 309-317.	0.5	0
43	The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells. Molecular Vision, 2012, 18, 1189-96.	1.1	39
44	Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells. Journal of Biochemical and Pharmacological Research, 2014, 2, 175-184.	1.7	5
45	A novel ophthalmic latanoprost 0.005% nanoemulsion: a cytotoxicity study. Graefe's Archive for Clinical and Experimental Ophthalmology, 2022, 260, 1941-1946.	1.9	5
46	Effect of travoprost, latanoprost and bimatoprost PGF2Î± treatments on the biomechanical properties of in-vivo rabbit cornea. Experimental Eye Research, 2022, 215, 108920.	2.6	5
47	Changes in Corneal Biomechanical Properties in PRK Followed by Two Accelerated CXL Energy Doses in Rabbit Eyes. Journal of Refractive Surgery, 2021, 37, 853-860.	2.3	3
48	Changes in ocular surface after withdrawal of anti-glaucoma medications following non-penetrating deep sclerectomy. Indian Journal of Ophthalmology, 2022, 70, 1626.	1.1	2
49	Current progress in preservative-free topical ophthalmic formulations. Journal of Drug Delivery Science and Technology, 2023, 79, 103996.	3.0	1
50	Ocular surface disease signs and symptoms of glaucoma patients and their relation to glaucoma medication in Finland. European Journal of Ophthalmology, 0, , 112067212211443.	1.3	0
51	The molecular aspect of anti-glaucomatous eye drops - are we harming our patients?. Molecular Aspects of Medicine, 2023, 93, 101195.	6.4	3
52	Pharmacokinetic and Ocular Toxicity Evaluation of Latanoprost Ophthalmic Solution, 0.005%, with Preservative Level Reduced to Below the Limit of Quantitation. Journal of Ocular Pharmacology and Therapeutics, 0, , .	1.4	0